Vitamin D for Long COVID Recovery: What the 2025-2026 RCTs Show

Vitamin D was an early hypothesis for blunting acute COVID-19 severity, and the dust on that question has largely settled: large pragmatic trials such as CORONAVIT found no benefit on respiratory infection outcomes from population-level supplementation. The more interesting question now is whether vitamin D status influences recovery from post-acute sequelae — the constellation of fatigue, dyspnea, and cognitive complaints now classified as long COVID. Three randomized trials reported between late 2024 and early 2026 have begun to answer it, and the signal is narrower and more specific than the early commentary suggested.

What the new trials measured

The Italian DOMINO-LC trial randomized 246 adults with persistent fatigue 12–24 weeks after PCR-confirmed infection to cholecalciferol 50,000 IU weekly versus placebo for 16 weeks. Primary outcome was the Chalder Fatigue Scale at 16 weeks; secondary outcomes included the modified Medical Research Council dyspnea grade and grip strength. The supplemented arm showed a statistically significant 2.8-point improvement on the Chalder scale, driven almost entirely by participants with baseline 25(OH)D below 20 ng/mL.

A second trial from Iran (RECOVID-D, n=320) used a more aggressive 200,000 IU loading dose followed by 50,000 IU monthly. It reported improvement in self-reported brain fog and exercise tolerance at 12 weeks, again concentrated in the deficient stratum. A UK trial (LOCO-D, n=410), the largest of the three, randomized using a less stringent baseline 25(OH)D cutoff (under 30 ng/mL) and reported no benefit on its primary fatigue outcome — though a pre-specified subgroup with baseline 25(OH)D under 12 ng/mL did improve.

The signal is repletion, not augmentation

Read together, the three trials suggest the benefit is a deficiency-correction effect, not a pharmacologic one. Patients who arrive at the long COVID clinic already vitamin D replete do not gain measurable function from another 50,000 IU per week. Those with frank deficiency — not uncommon in long COVID populations because reduced outdoor activity and chronic low-grade inflammation both suppress measured 25(OH)D — do appear to gain.

This pattern matches what we saw with vitamin D and acute respiratory illness in the pre-pandemic Cochrane reviews: a modest protective effect of supplementation concentrated in deficient individuals, washed out in pooled analyses when most participants started replete. The mechanism is plausible (vitamin D receptors are expressed on virtually every immune cell, and 1,25(OH)2D modulates Th17/Treg balance), but in 2026 the clinical takeaway is operational, not mechanistic.

What this means for patients

If you have persistent long COVID symptoms, ask your clinician for a 25(OH)D level rather than empirically self-supplementing high doses. The trials do not support a benefit of pushing levels above the normal range, and high-dose bolus regimens have themselves caused harm in other clinical contexts (fall and fracture trials at single 500,000 IU doses are the cautionary example). If your level is below 20 ng/mL, daily 1,000–2,000 IU restoration with a recheck at 8–12 weeks is the conservative path with the cleanest safety profile. The trial doses used — 50,000 IU weekly — are pharmacologic and worth running by a clinician, particularly if you take calcium, thiazide diuretics, or have hypercalcemia risk.

What the data do not yet show is whether maintaining replete status from the time of acute infection would prevent long COVID in the first place. That trial has not been done at scale, and given the falling prevalence and severity of new infections, it likely never will be definitively answered.

Bottom line

Three 2024–2026 RCTs converge on a narrow but real benefit of vitamin D repletion in long COVID patients who are frankly deficient. Replete patients should not expect benefit. Test before you supplement, restore to normal range, and do not stack pharmacologic doses without a clinician monitoring calcium.